X0508 4 2026-03-16 false 0001831363 Terns Pharmaceuticals, Inc. TERN 0001872564 Burroughs Amy L. C/O TERNS PHARMACEUTICALS, INC. 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 true true false false Chief Executive Officer true Common Stock 2026-03-16 4 M false 14583.00 4.64 A 303559.00 D Common Stock 2026-03-16 4 S false 11813.00 46.5657 D 291746.00 D Common Stock 2026-03-16 4 S false 2770.00 47.3024 D 288976.00 D Common Stock 8319.00 I Trust Stock Option (Right to Buy) 4.64 2026-03-16 4 M false 14583.00 0.00 D 2035-01-29 Common Stock 14583.00 955534.00 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. This sale price represents the weighted average sale price of the shares sold ranging from $46.01 to $47.005 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This sale price represents the weighted average sale price of the shares sold ranging from $47.01 to $47.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The Reporting Person beneficially owns these shares indirectly through the Amy L Burroughs 2017 Trust. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. /s/ David Strauss, as Attorney-in-Fact for Amy L. Burroughs 2026-03-17